
Ashvattha Therapeutics secures $50M in financing to advance clinical trials
Key Takeaways
- Ashvattha Therapeutics received $50 million funding to support Phase 2 ophthalmology and Phase 1/2 neuroinflammation trials.
- The platform targets activated innate immune cells, with potential applications in inflammation, cancer, and neurological diseases.
The new funding will allow the company to complete its ongoing Phase 2 trial of proprietary nanomedicine, migaldendranib, in patients with wet AMD and DME
Ashvattha Therapeutics announced it has received additional funding of up to $50 million from investors Tribe Capital and Natural Capital. The funding will assist with the extension of its Series B and enable Ashvattha to complete the ongoing Phase 2 ophthalmology trial and Phase 1/2 neuroinflammation trial.
“We believe Ashvattha is a broad platform for HDTs to target and reprogram activated innate immune cells in the human body,” Arjun Sethi, chief investment officer of Tribe Capital, said. “These cells are implicated in inflammation, cancer, heart disease, aging disorders, autoimmune and neurological diseases. Built on over twenty years of work at Johns Hopkins, with four safety studies and three Phase 2a trials under the belt, we believe the platform of over one hundred HDTs has reached a point where we can see its impact on the human population in the next few years.”
The current Phase 2 study in wet
“These interim results validate our novel approach of developing an at-home subcutaneous injection to treat both eyes in patients with bilateral disease from a single administration,” Jeff Cleland, PhD, CEO of Ashvattha Therapeutics, said. “Unlike all other clinical-stage approaches, we have demonstrated a benefit to patients with bilateral disease with a well-tolerated systemic therapy. Over 40% of wet AMD and over 90% of DME subjects in our trial had bilateral disease that would require both eyes to receive injections of current products or clinical candidates. We look forward to sharing detailed results at upcoming medical conferences in 2025.”
The interim results will be presented at the Angiogenesis meeting on February 8, 2025.
Reference:
Ashvattha Therapeutics Announces $50 Million Financing Extension and Interim Phase 2 Ophthalmology Trial Results. News release. GlobeNewswire. Accessed January 13, 2025.
Ashvattha Therapeutics Announces $50 Million Financing
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.